

Product Information

Product ID S3345

CAS No. 65666-07-1

Chemical Name

Synonym Apihepar, Laragon, Legalon, Pluropon, Silarine, Silliver


Formula $C_{25}H_{22}O_{10}$

Formula Wt. 482.44

Melting Point

Purity $\geq 70\%$

Solubility Soluble in DMSO or ethanol.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
S3345	10 g	\$44.70
S3345	50 g	\$126.80

Store Temp 4° C

Ship Temp Ambient

Description Silymarin is a flavanolignan mixture found in *Silybum* (milk thistle) seeds; it exhibits antiviral, anti-inflammatory, anti-fibrotic, hepatoprotective, neuroprotective, immunosuppressive, antioxidative, and anticancer activities. Silymarin inhibits influenza virus proliferation by suppressing viral RNA synthesis. In animal models of benign prostatic hyperplasia (BPH), silymarin decreases inflammation, collagen deposition, and levels of iNOS, COX-2, NF- κ B, IL-6, IL-8, and HIF-1 α . In animal models of fibrosis, silymarin decreases oxidative stress, fibrosis development, and levels of α -SMA and TGF- β 1. Silymarin shows potential benefit in models of Parkinson's disease and Alzheimer's disease, inhibiting aggregation of proteins such as amyloid- β (A β). In activated T cells, silymarin induces G1 phase cell cycle arrest and decreases mTOR signaling. This compound decreases lipid peroxidation and increases radical scavenging and levels of glutathione in vivo. In ovarian cancer cells, silymarin increases expression of PTEN, decreases signaling by Akt and expression of Bcl-2, induces apoptosis, and inhibits cellular proliferation; it also inhibits telomerase activity.

References Sato M, Murakami K, Uno M, et al. Structure-activity relationship for (+)-taxifolin isolated from silymarin as an inhibitor of amyloid-beta aggregation. *Biosci Biotechnol Biochem.* 2013;77(5):1100-1103. PMID: 23649236.

Atawia RT, Mosli HH, Tadros MG, et al. Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1 α , and NF- κ B. *Naunyn Schmiedebergs Arch Pharmacol.* 2014 Aug 28. [Epub ahead of print]. PMID: 25164963

Clichici S, Olteanu D, Nagy AL, et al. Silymarin Inhibits the Progression of Fibrosis in the Early Stages of Liver Injury in CCl4-Treated Rats. *J Med Food.* 2014 Aug 18. [Epub ahead of print]. PMID: 25133972.

Borah A, Paul R, Choudhury S, et al. Neuroprotective potential of silymarin against CNS disorders: insight into the pathways and molecular mechanisms of action. *CNS Neurosci Ther.* 2013 Nov;19(11):847-53. PMID: 24118806.

Su CH, Chen LJ, Liao JF, et al. Increase of phosphatase and tensin homolog by silymarin to inhibit human pharynx squamous cancer. *J Med Food.* 2013 Sep;16(9):778-84. PMID: 23909904.

Kwon do Y, Jung YS, Kim SJ, et al. Alterations in sulfur amino acid metabolism in mice treated with silymarin: a novel mechanism of its action involved in enhancement of the antioxidant defense in liver. *Planta Med.* 2013 Aug;79(12):997-1002. PMID: 23807810.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.